Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director · CHAIRMAN AND CEO | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 306,461 |
Ending reported balance
After 2026-08-25 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 151,869 · Balance 458,330 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 246,963 · Balance 705,293 Row 3 · 2026-08-25 · Sale · Disposed 218,535 · Balance 486,758 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2026-08-25 · Sale · Disposed 180,297 · Balance 306,461 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.40 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2026-08-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-25 · Exercise / conversion · Disposed 151,869 · Balance 0 F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.94 · Expires 2028-02-15 | Direct | 0 |
Reported balance
After 2026-08-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-25 · Exercise / conversion · Disposed 246,963 · Balance 0 F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectFord Family Trust | 216,203 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 216,203 F3: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.
F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.85 | $12,569.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 10 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,206 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.84 | $6,284.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 9 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,406 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 527 | $62.83 | $33,111.41 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 8 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,506 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.83 | $6,282.50 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 7 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,033 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $62.82 | $18,846.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 6 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,133 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.81 | $12,562.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 5 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,433 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 49,000 | $34.94 | $1,712,060.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 4 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 19,600 | $27.03 | $529,858.56 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,400 | $22.39 | $232,875.76 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,467 | $26.19 | $116,981.35 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2017 Filed Jul 6, 2017 00:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,618 | $48.61 | $78,650.98 |
DisclosureSEC source: 0001179110-17-010122 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,166 Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 352 | $45.66 | $16,072.32 |
DisclosureSEC source: 0001179110-17-008473 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,784 Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 10,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004830 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 80,212 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 10,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004830 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,136 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,685 | $45.46 | $394,820.10 |
DisclosureSEC source: 0001179110-17-003667 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,806 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 151,869 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002923 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,869 Underlying: Common shares · 151,869 shares Expires 2027-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 50,623 on 02/17/2018, 50,623 on 02/17/2019, and 50,623 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002923 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,491 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 1,300 | $39.08 | $50,797.50 |
DisclosureSEC source: 0001179110-16-033129 · edgar.xml · nonDerivative · entry 7 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 69,542 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 200 | $39.08 | $7,815.60 |
DisclosureSEC source: 0001179110-16-033129 · edgar.xml · nonDerivative · entry 6 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 68,242 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 600 | $39.08 | $23,448.00 |
DisclosureSEC source: 0001179110-16-033129 · edgar.xml · nonDerivative · entry 5 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 68,042 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 10,575 | $39.09 | $413,376.75 |
DisclosureSEC source: 0001179110-16-033129 · edgar.xml · nonDerivative · entry 4 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 67,442 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 100 | $39.08 | $3,907.50 |
DisclosureSEC source: 0001179110-16-033129 · edgar.xml · nonDerivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 56,867 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033129 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 56,767 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-033129 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,532 Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,618 | $39.31 | $63,603.58 |
DisclosureSEC source: 0001179110-16-027476 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,336 Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 352 | $39.63 | $13,949.76 |
DisclosureSEC source: 0001179110-16-025992 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,954 Read SEC document |
| March 24, 2016 Filed Apr 1, 2016 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 5,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-022545 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 54,963 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| March 24, 2016 Filed Apr 1, 2016 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 5,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-022545 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,306 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,306 | $39.29 | $51,306.21 |
DisclosureSEC source: 0001179110-16-020740 · edgar.xml · nonDerivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,789 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $39.28 | $15,713.60 |
DisclosureSEC source: 0001179110-16-020740 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,095 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,483 | $39.52 | $177,168.16 |
DisclosureSEC source: 0001179110-16-020740 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,495 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 285,388 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019902 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,388 Underlying: Common shares · 285,388 shares Expires 2026-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 95,130 on 02/19/2017, 95,129 on 02/19/2018, and 95,129 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 32,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019902 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,978 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| August 05, 2015 Filed Aug 7, 2015 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-011904 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 49,480 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| August 05, 2015 Filed Aug 7, 2015 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-011904 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,426 Read SEC document |
| July 01, 2015 Filed Jul 2, 2015 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,682 | $49.08 | $82,552.56 |
DisclosureSEC source: 0001179110-15-010821 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,844 Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 21:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 14,423 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-15-009077 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,423 Underlying: Common shares · 14,423 shares Expires 2025-05-31 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,808 on 6/1/2016, 4,807 on 6/1/2017, and 4,808 on 6/1/2018. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 21:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-009077 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,526 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 01, 2015 Filed Aug 20, 2015 21:19 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 14,243 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-15-012424 · edgar.xml · derivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,243 Underlying: Common shares · 14,243 shares Expires 2025-05-31 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,748 on 6/1/2016, 4,747 on 6/1/2017, and 4,748 on 6/1/2018. F2 · shares: This Form 4/A amends the number of derivative securities acquired on June 1, 2015. F2 · derivative.underlying_shares: This Form 4/A amends the number of derivative securities acquired on June 1, 2015. F2 · balance_after: This Form 4/A amends the number of derivative securities acquired on June 1, 2015. Read SEC document |
| May 01, 2015 Filed May 8, 2015 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 48,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-007426 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 48,062 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| May 01, 2015 Filed May 8, 2015 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 48,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-007426 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,505 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,680 | $47.61 | $175,204.80 |
DisclosureSEC source: 0001179110-15-004045 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,567 Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 127,436 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003369 · edgar.xml · derivative · entry 2 Ford Robert B · CIK 0001612571 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,436 Underlying: Common shares · 127,436 shares Expires 2025-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 42,479 on 2/20/16, 42,478 on 2/20/17, and 42,479 on 2/20/18. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003369 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,247 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 56,933 | $0.00 Strike: $41.14 | $0.00 |
DisclosureSEC source: 0001179110-14-011500 · edgar.xml · derivative · entry 2 Ford Robert B · CIK 0001612571 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,933 Underlying: Common shares · 56,933 shares Expires 2024-06-30 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,978 on 7/1/2015, 18,977 on 7/1/2016, and 18,978 on 7/1/2017. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-011500 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,162 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.